



Lovaltech

LVT-001, a unique mucosal vaccine to stop viral infection contagiousness



Serge PAMPFER


serge.pampfer@lovaltechnology.com



Contagiousness is a primary driver
of pandemic breakouts


Strategy

Activation of the
mucosal immune system




Challenge

Bypassing
mucociliary clearance






Solution

Lovaltech
vaccine R&D platform



LVT-001 : Blocking Covid transmission



LVT-001 : Key advantages and perspectives

LovalTech

Triggers mucosal immunity
Prevents viral transmission
Protects against multi-variants



No adjuvant in formulation
No needle for administration
Stable at positive temperature

GMP-produced antigen and excipient
Clinical trial phase I to start by Q4 2024





Lovaltech platform and pipeline

Complex
antigen
design




Nasal
delivery
device

Muco-
adhesive
excipient




Mucosal
immunity
expertise


Flu
LVT-002




RSV
LVT-004



Malaria
LVT-003



Nipah
LVT-005





Thank you very much !



Serge PAMPFER
serge.pampfer@lovaltechnology.com